Home News General Health News AI Algorithm Accurately IDs Two Life-Threatening Heart Conditions

AI Algorithm Accurately IDs Two Life-Threatening Heart Conditions

Model can distinguish between hypertrophic cardiomyopathy and cardiac amyloidosis using ultrasound videos

MONDAY, March 14, 2022 (HealthDay News) — An artificial intelligence (AI) tool can effectively identify and distinguish between two life-threatening heart conditions from ultrasound videos, according to a study published online Feb. 23 in JAMA Cardiology.

Grant Duffy, from Cedars-Sinai Medical Center in Los Angeles, and colleagues assessed the accuracy of a deep learning workflow to quantify ventricular hypertrophy and predict the cause of increased left ventricular (LV) wall thickness. The analysis included ultrasound videos from 23,745 patients seen at two health care systems.

The researchers found that the deep learning algorithm accurately measured intraventricular wall thickness, LV diameter, and posterior wall thickness, and they classified cardiac amyloidosis (area under the curve [AUC], 0.83) and hypertrophic cardiomyopathy (AUC, 0.98) separately from other causes of LV hypertrophy. When using external validation data sets from independent domestic and international health care systems, the deep learning algorithm accurately quantified ventricular parameters (domestic: R2, 0.96; international: R2, 0.90). Mean absolute error was 1.7 mm for intraventricular septum thickness, 3.8 mm for LV internal dimension, and 1.8 mm for LV posterior wall thickness in the domestic data set and 1.7 mm, 2.9 mm, and 2.3 mm, respectively, in the international data set. In the domestic set, the algorithm accurately detected cardiac amyloidosis (AUC, 0.79) and hypertrophic cardiomyopathy (AUC, 0.89).

“The algorithm identified high-risk patients with more accuracy than the well-trained eye of a clinical expert,” a coauthor said in a statement. “This is because the algorithm picks up subtle cues on ultrasound videos that distinguish between heart conditions that can often look very similar to more benign conditions, as well as to each other, on initial review.”

Three authors disclosed having a patent pending for EchoNet-LVH; several authors disclosed financial ties to the pharmaceutical and medical technology industries.

Abstract/Full Text

Copyright © 2021 HealthDay. All rights reserved.